| Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Cancer discovery 6 (10), 1118-1133, 2016 | 1127 | 2016 |
| Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ... New England Journal of Medicine 374 (1), 54-61, 2016 | 536 | 2016 |
| Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer JF Gainor, D Tseng, S Yoda, I Dagogo-Jack, L Friboulet, JJ Lin, ... JCO precision oncology 1, 1-13, 2017 | 282 | 2017 |
| Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer S Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet, A Langenbucher, ... Cancer discovery 8 (6), 714-729, 2018 | 279 | 2018 |
| Primary patient-derived cancer cells and their potential for personalized cancer patient care DP Kodack, AF Farago, A Dastur, MA Held, L Dardaei, L Friboulet, ... Cell reports 21 (11), 3298-3309, 2017 | 206 | 2017 |
| SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512-517, 2018 | 191 | 2018 |
| Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA I Dagogo-Jack, AR Brannon, LA Ferris, CD Campbell, JJ Lin, KR Schultz, ... JCO precision oncology 2, 1-14, 2018 | 133 | 2018 |
| Molecular mechanisms of resistance to first-and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016; 6: 1118–1133. doi: 10.1158/2159-8290 JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... CD-16-0596.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 110 | |
| Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β–SMAD3 pathway in non-small cell lung adenocarcinoma M Risolino, N Mandia, F Iavarone, L Dardaei, E Longobardi, S Fernandez, ... Proceedings of the National Academy of Sciences 111 (36), E3775-E3784, 2014 | 95 | 2014 |
| Molecular mechanisms of resistance to first-and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016; 6 (10): 1118–1133. doi: 10.1158/2159-8290 JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ... Přejít k původnímu zdroji... Přejít na PubMed, 2013 | 64 | 2013 |
| A tale of TALE, PREP1, PBX1, and MEIS1: Interconnections and competition in cancer F Blasi, C Bruckmann, D Penkov, L Dardaei Bioessays 39 (5), 1600245, 2017 | 59 | 2017 |
| Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis L Dardaei, E Longobardi, F Blasi Proceedings of the National Academy of Sciences 111 (10), E896-E905, 2014 | 58 | 2014 |
| Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018; 8 (6): 714–729. doi: 10.1158/2159-8290 S Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet, A Langenbucher, ... ALKF1174L ALKF1174L ALKL1196Q ALKC1156Y ALKG1269A ALKR1264K ALKF1174L …, 0 | 44 | |
| Homeodomain transcription factor and tumor suppressor Prep1 is required to maintain genomic stability G Iotti, E Longobardi, S Masella, L Dardaei, F De Santis, N Micali, F Blasi Proceedings of the National Academy of Sciences 108 (29), E314-E322, 2011 | 42 | 2011 |
| Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells M Momeny, F Moghaddaskho, NK Gortany, H Yousefi, Z Sabourinejad, ... Scientific Reports 7 (1), 44075, 2017 | 37 | 2017 |
| Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells M Momeny, Z Sabourinejad, G Zarrinrad, F Moghaddaskho, H Eyvani, ... Scientific reports 7 (1), 45954, 2017 | 34 | 2017 |
| Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells M Momeny, G Zarrinrad, F Moghaddaskho, A Poursheikhani, ... Scientific Reports 7 (1), 4204, 2017 | 33 | 2017 |
| Tumorigenesis by Meis1 overexpression is accompanied by a change of DNA target-sequence specificity which allows binding to the AP-1 element L Dardaei, D Penkov, L Mathiasen, P Bora, MJ Morelli, F Blasi Oncotarget 6 (28), 25175, 2015 | 16 | 2015 |
| The deficiency of tumor suppressor prep1 accelerates the onset of meis1-hoxa9 leukemogenesis L Dardaei, L Modica, G Iotti, F Blasi PloS one 9 (5), e96711, 2014 | 9 | 2014 |
| SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged non-small cell lung cancer L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512, 2018 | 3 | 2018 |
